SCHEMBL4675284

SCHEMBL4675284

COc1ccccc1Oc1cocc1C(=O)C=C(O)c1nc[nH]n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.40
POLB P06746 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
CA12 O43570 1/20 0.34
CA1 P00915 1/20 0.34
CA2 P00918 1/20 0.34
CA9 Q16790 1/20 0.34
HSD17B10 Q99714 2/20 0.33
KMT2A Q03164 5/20 0.33
MEN1 O00255 4/20 0.33
GPR52 Q9Y2T5 1/20 0.32
LMNA P02545 1/20 0.32
CYP1A1 P04798 1/20 0.32
ABCB1 P08183 1/20 0.32
CYP1B1 Q16678 1/20 0.32
ALDH1A1 P00352 2/20 0.31
ABCG2 Q9UNQ0 1/20 0.31
SRC P12931 1/20 0.31
TGFBR1 P36897 1/20 0.31
MAPT P10636 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4676769 0.87 CXCL8 (0.36) HTTPOLBSMN1; SMN2KMT2AMEN1
SCHEMBL4673539 0.87 CTNNB1 (0.33) HTTSMN1; SMN2ALDH1A1MAPTGAA
SCHEMBL4671775 0.86 GAA (0.34) POLBSMN1; SMN2KMT2AMEN1LMNA
SCHEMBL4672407 0.85 KDM4E (0.45) HTTPOLBHSD17B10KMT2AMEN1
SCHEMBL4675422 0.85 RXRA (0.33)
SCHEMBL4679493 0.82 AR (0.37) POLBSMN1; SMN2LMNAKDM4E
SCHEMBL4674906 0.82 CYP1A1 (0.40) HTTPOLBSMN1; SMN2CA12CA1
SCHEMBL4670767 0.81 HTT (0.38) HTTPOLBSMN1; SMN2CA12CA1
SCHEMBL4671741 0.80 MAPT (0.37) SMN1; SMN2LMNAALDH1A1MAPTGAA
SCHEMBL4673572 0.80 ICAM1 (0.31)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 HTT 1204/4885POLB 58/4885SMN1; SMN2 4107/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.